A Single-Arm, Open-Label, Phase I Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogenic CAR T Cell Therapy, and ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients with Relapsed/Refractory Large B-Cell or Follicular Lymphoma
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
A Single-Arm, Open-Label, Phase I/II Study Evaluating the Safety, Efficacy, and Cellular Kinetics / Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogenic Car-T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed / Refractory Large B-Cell Lymphoma (LBCL)
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
Phase 1-2 Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T-Cell Depleted Graft with Infusion of Conventional T-Cells and Regulatory T-Cells
A Phase I, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived From Mobilized Peripheral Blood (Orca-Q, Formerly OrcaGraft), with Single-Agent Graft-Versus-Host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
CD34 Selected Allogeneic Hematopoietic Cell Transplantation with Myeloablative Conditioning and CD8+ Memory T cell Infusion For Patients with Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous Leukemia
A Multicenter Phase Ib Trial for Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Orca-T, a T-Cell-Depleted Graft with Additional Infusion of Conventional T Cells and Regulatory T Cells
A Phase Ia/b Study to Evaluate the Safety and Tolerability of JSP191 in Combination with a Conditioning Regimen of Low Dose Radiation and Fludarabine in Subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination with Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
A Phase 1 Open-Label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
A Single-Arm, Open-Label, Phase I Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy with and without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination with Other Agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS)
A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Study Evaluating the Safety and Efficacy of MGTA-145 in Combination with Plerixafor for the Mobilization and Transplantation of HLA-Matched Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies